HOME >> MEDICINE >> NEWS
Comparison of drug-releasing coronary stents show similar effectiveness

Use of coronary stents that release the drugs sirolimus or paclitaxel produced similar results in patients with new coronary artery lesions, according to a study in the February 22 issue of JAMA.

Stents that release sirolimus or paclitaxel have been known to be more effective than bare metal stents in improving angiographic (examination of the blood vessels using x-rays) and clinical outcomes after percutaneous coronary revascularization (procedures such as angioplasty in which a catheter-guided balloon is used to open a narrowed coronary artery). These drugs are effective after these procedures because they inhibit the growth of cells in blood vessels. It has not been clear if one drug-releasing stent is more effective than another, according to background information in the article.

Marie-Claude Morice, M.D., of the Institut Cardiovasculaire Paris Sud, Massy, France and colleagues compared the safety and efficacy of sirolimus-eluting vs. paclitaxel-eluting coronary stents in patients with new coronary artery lesions. The REALITY trial included 1,386 patients with angina pectoris (a heart condition marked by chest pain due to reduced blood flow to the heart) and 1 or 2 new coronary lesions. The study was conducted at 90 hospitals in Europe, Latin America, and Asia between August 2003 and February 2004, with angiographic follow-up at 8 months and clinical follow-up at 12 months. Patients were randomly assigned to receive a sirolimus-eluting (releasing) stent or a paclitaxel-eluting stent.

The researchers found that the average restenosis (narrowing again of a coronary artery after treatment) rate, the primary study outcome the researchers were using to compare the stents, was 9.6 percent in the sirolimus-eluting stent group vs. 11.1 percent in the paclitaxel-eluting stent group, a difference that did not reach statistical significance. Likewise, there were no significant differences between the 2 study groups in rates of other in-hospital ad
'"/>

Contact: Marie-Claude Morice, M.D.
mc.morice@icps.com.fr
JAMA and Archives Journals
21-Feb-2006


Page: 1 2

Related medicine news :

1. Comparison of obstetric outcomes between on-call and patients own obstetricians
2. Comparison of patients access to new and better cancer drugs reveals inequalities between countries
3. Comparison of 4 diet plans shows better outcomes for diet with lowest carbohydrate intake
4. New biodegradable magnesium stents for coronary arteries
5. Same-day coronary angiography and surgery safe for many patients
6. Experts debate role of stenting, bypass surgery in left main coronary artery disease
7. Acute coronary syndrome therapy improvements linked with fewer deaths and improved clinical outcomes
8. Exercise can cut coronary artery disease risk for some with MS
9. Having elevated risk factors in young adulthood raises risk of coronary calcium later on
10. Study finds coronary procedure adds no benefit over optimal medical therapy alone
11. Pairing medical therapy with coronary intervention fails to reduce heart disease deaths

Post Your Comments:
(Date:4/27/2015)... Churchview Supportive Living, a Gardant affordable assisted living community, ... from 10:30 a.m. to noon on May 8. , ... St. in Chicago, serves low-income older adults, including those ... independence. , “Mothers, grandmothers, godmothers and mothers-to-be are invited ... Director of Marketing Elizabeth Clippard. , The menu will ...
(Date:4/27/2015)... 2015 Medical Device Design Control , ... Ombu Enterprises**, June 16-17, 2015 – Chicago, IL , ... to a facility today, would the design control system ... is "maybe" or "no" … then very likely there ... a solution. , Take this important step. Enroll ...
(Date:4/27/2015)... How to Implement UDI:, Lessons from Early ... – 3:00 p.m. EDT, http://www.fdanews.com/HowToImplementUDI , With ... restraint, there’s plenty of time to get ready for ... deadlines are coming fast for all devicemakers and soon ... even if it seems there’s no rush. It's already ...
(Date:4/27/2015)... NY (PRWEB) April 28, 2015 ... new white paper called “Website Anatomy 101.” ... paper discusses the necessary design elements for a ... emphasis on responsive design, user experience, search results ... the impact of a well-designed website on patient ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Women may ... from concussion, according to a new study published online ... mild traumatic brain injury (MTBI), is a common medical ... some individuals. , In most cases, patients who ... Ten to 15 percent of MTBI patients will continue ...
Breaking Medicine News(10 mins):Health News:Churchview Supportive Living Community in Chicago to Host Mother's Day Brunch 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 2Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 3Health News:FDAnews Announces: Medical Device Design Control: Implementing an Approach That Works, June 16-17, Chicago, IL 4Health News:FDAnews Announces: How to Implement UDI: Lessons from Early Adopters Webinar, May 20, 2015 2Health News:FDAnews Announces: How to Implement UDI: Lessons from Early Adopters Webinar, May 20, 2015 3Health News:Smith & Jones Publishes 2015 Website Design White Paper 2Health News:Women Show Persistent Memory Impairment after Concussion 2Health News:Women Show Persistent Memory Impairment after Concussion 3
(Date:4/27/2015)...  Together with its parent partners and the Community ... initiative of Morris County Prevention is Key (MCPIK), the ... community effort to address the heroin/opiate crisis in ... Volunteer Parent Coaches from the Partnership, ... Denise Mariano , National Council on Alcoholism and Drug ...
(Date:4/27/2015)... 2015 PAML announced today that the ... Axela, Inc. to develop multiplex assays focused on ... of the nation,s leading medical reference laboratories, and ... analysis for clinical diagnostics. Axela,s ... assay development serves as the foundation for novel ...
(Date:4/27/2015)... Calif. , April 27, 2015  Eiger BioPharmaceuticals, ... Phase 2 data of lonafarnib in patients with chronic ... the LOWR HDV program, enrolled at Ankara University Medical ... where HDV is endemic. LOWR HDV ... parallel dose comparison study which randomized subjects to receive ...
Breaking Medicine Technology:Partnership for Drug-Free Kids Brings Life-Saving Kits and Training to New Jersey Families 2Partnership for Drug-Free Kids Brings Life-Saving Kits and Training to New Jersey Families 3PAML and Axela Collaborate on Immune Status for Vaccine Preventable Diseases 2Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 2Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 3
Cached News: